Predicting lymph node metastases in three different vulvar squamous cell carcinoma subgroups

Gynecologic Oncology, vol. 194, pp. 86–90

Abstract

OBJECTIVE: This study aimed to analyze the risk of lymph node metastases (LNM) in three different VSCC subgroups (HPV-positive (HPVpos), HPV-negative p53 wildtype (HPVneg/p53wt) and HPV-negative p53 abnormal (HPVneg/p53abn)), and develop a predictive model for clinical use. METHODS: A retrospective cohort study was performed, collecting data from all surgically treated VSCC patients between 2000 and 2022 from two oncology clinics. The primary outcome was the risk of groin LNM at diagnosis. Prognostic variables for LNM were identified using uni- and multivariate analyses. A model was created to estimate the probability of LNM at diagnosis. RESULTS: A total of 516 patients were included, of which 94 (18.2 %) were HPVpos, 117 (22.7 %) HPVneg/p53wt, and 305 (59.1 %) HPVneg/p53abn. LNM rates were 17.0 %, 26.5 %, and 35.1 %, respectively (p = .002). Molecular subgroup remained a significant predictor of LNM after adjusting for age, tumor size, and depth of invasion (p = .028). A model using these variables was developed to predict LNM at diagnosis. CONCLUSION: HPVneg/p53abn VSCCs have a higher risk of LNM compared to HPVpos VSCCs. HPVneg/p53wt VSCC are considered an intermediate risk group. Molecular subgroups contribute to LNM risk assessment at diagnosis. We developed a well-performing, clinically feasible model to predict the risk of LNM at diagnosis.

Authors 7

1. Anne Fleur van Velzen Aachen Department of Gynecology, Leiden University Medical Center

   Leiden University Medical Center

   Affiliation as printed

   Department of Gynecology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands

2. Adam J. Tulling Aachen Department of Pediatrics, Willem-Alexander Children's Hospital

   Leiden University Medical Center · Willem-Alexander Kinderziekenhuis

   Affiliation as printed

   Department of Pediatrics, Willem-Alexander Children's hospital, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands

3. Mariëtte I.E. van Poelgeest Aachen Department of Gynecology, Leiden University Medical Center

   Leiden University Medical Center

   Affiliation as printed

   Department of Gynecology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands

4. Tjalling Bosse Aachen Department of Pathology, Leiden University Medical Center

   Leiden University Medical Center

   Affiliation as printed

   Department of Pathology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands

5. Helena C. van Doorn

   Erasmus MC · Erasmus MC Cancer Institute

   Affiliation as printed

   Department of Gynecologic Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands

6. Kim E. Kortekaas Aachen Department of Gynecology, Leiden University Medical Center

   Leiden University Medical Center

   Affiliation as printed

   Department of Gynecology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands

7. Linda Suzanne Nooij corresponding Aachen Department of Gynecology, Leiden University Medical Center

   Leiden University Medical Center

   Affiliation as printed

   Department of Gynecology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. Electronic address: l.s.nooij@lumc.nl